Myocholine (Bethanechol Chloride)

Bethanechol, the active ingredient in Myocholine, is a muscarinic agonist presented as an oral formulation for oral use. It stimulates smooth muscle in the urinary bladder and gastrointestinal tract, helping to restore normal voiding and intestinal motility in postoperative patients and those with neurogenic dysfunction. GNH USA supplies Myocholine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Myocholine (bethanechol) acts on the muscarinic cholinergic pathway to improve smooth‑muscle contractility in several clinical settings.

Post‑operative urinary retention: enhances bladder contraction to facilitate voiding after surgery. Neurogenic bladder dysfunction: improves detrusor activity in patients with spinal cord injury or neurological disease. Post‑operative ileus: stimulates gastrointestinal motility to reduce bowel stasis after abdominal procedures.

Myocholine may cause a range of cholinergic‑related adverse reactions.

Common Side Effects: - Abdominal cramps or discomfort - Diarrhea or loose stools - Increased salivation or drooling - Sweating and flushing - Nausea or mild vomiting - Urinary urgency or frequency

Serious or Rare Side Effects: - Bronchospasm or respiratory difficulty - Severe hypotension or syncope - Cardiac arrhythmias, especially bradycardia - Cholinergic crisis with muscle weakness - Incontinence due to excessive bladder contraction

Before initiating therapy, clinicians should consider patient‑specific risk factors and monitor for adverse effects. - Assess renal and hepatic function: adjust dose if impairment is present. - Monitor for cholinergic signs: excessive salivation, sweating, or gastrointestinal upset. - Avoid in patients with uncontrolled asthma or severe COPD. - Use caution in cardiovascular disease: risk of hypotension and bradycardia. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Bethanechol may interact with other medications that influence cholinergic activity.

Major Interactions (Avoid): - Anticholinergic agents (e.g., atropine, scopolamine): may block therapeutic effect. - Other cholinergic drugs (e.g., pilocarpine): risk of additive cholinergic toxicity. - MAO inhibitors: can potentiate muscarinic stimulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardic response. - Diuretics: increase risk of hypotension. - Opioids: may mask gastrointestinal side effects. - Antihistamines with anticholinergic properties: may reduce efficacy.